000504 *ST南华生物
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-1.481-8.034-20.795-81.291-88.528
总资产报酬率 ROA (%)-0.579-2.877-4.253-2.055-3.147
投入资产回报率 ROIC (%)-0.778-4.413-8.426-6.075-12.780

边际利润分析
销售毛利率 (%)63.94867.41668.06364.79270.831
营业利润率 (%)-27.566-15.481-33.419-13.052-19.579
息税前利润/营业总收入 (%)-28.722-15.686-26.025-4.978-10.368
净利润/营业总收入 (%)-27.258-17.795-34.198-14.704-21.135

收益指标分析
经营活动净收益/利润总额(%)93.54716.19646.05332.10162.241
价值变动净收益/利润总额(%)-22.404-17.662-2.1330.2551.033
营业外收支净额/利润总额(%)2.5940.180-2.246-21.290-1.447

偿债能力分析
流动比率 (X)1.5751.3161.4480.9150.977
速动比率 (X)1.5161.2041.4240.9050.956
资产负债率 (%)55.01553.63260.50385.50983.266
带息债务/全部投入资本 (%)46.06644.27640.10585.15781.178
股东权益/带息债务 (%)112.760119.935141.4677.62110.552
股东权益/负债合计 (%)71.35672.69055.0542.9613.031
利息保障倍数 (X)68.10588.422-3.907-0.861-1.161

营运能力分析
应收账款周转天数 (天)457.961351.848371.056318.839442.373
存货周转天数 (天)252.820183.74362.46738.635100.751